Soligenix (SNGX) Corporate presentation summary

Strategic focus and business overview

• Focuses on developing and commercializing therapies for rare diseases with unmet medical needs, targeting oncology, inflammation, and public health threats.

• Operates two segments: Specialized BioTherapeutics for orphan diseases and Public Health Solutions for vaccines and therapeutics addressing biothreats and infectious diseases.

Pipeline and clinical development

• Pipeline includes multiple fast track/orphan designated assets, with HyBryte for cutaneous T-cell lymphoma (CTCL) in late-stage development and positive Phase 3 data.

• SGX302 for mild-to-moderate psoriasis and SGX945 for Behçet's Disease have shown positive proof-of-concept and Phase 2a results.

• Public Health Solutions segment advancing vaccines for ricin, filoviruses (Ebola, Marburg), and COVID-19, supported by significant NIH funding.

Market opportunity and commercialization

• Estimated global annual sales potential of ~$2B across the pipeline, with HyBryte targeting a $250M market, SGX302 over $1B, and SGX945 over $200M.

• HyBryte offers rapid, safe, and effective treatment for CTCL, addressing a clear unmet need with favorable clinician feedback and efficient commercialization plans.

• SGX302 targets the large mild-to-moderate psoriasis population, offering advantages over UV-based therapies.